Arcutis Biotherapeutics Inc
ARQT14.600USD
+0.310+2.17%
交易中 （美东）报价延迟15分钟
1.74B总市值
亏损市盈率 TTM
关于 Arcutis Biotherapeutics Inc 公司
Arcutis Biotherapeutics, Inc. 是一家商业阶段的医学皮肤病学公司。该公司专注于开发和商业化具有高度未满足医疗需求的皮肤病治疗方法。其产品组合包括局部和全身治疗，具有治疗免疫介导的皮肤病和病症的潜力。其主打产品 ZORYVE 用于治疗 12 岁或以上人群的斑块状银屑病，包括间擦区域的银屑病。ZORYVE 乳膏是罗氟司特的每日一次局部制剂，罗氟司特是一种强效且选择性的磷酸二酯酶 4 (PDE4) 抑制剂。该公司的产品线包括 ARQ-255、ARQ-252 和 ARQ-234。ARQ-255 是为斑秃开发的。ARQ-252 是伊伐替尼的替代局部乳膏制剂，该公司正在开发用于治疗慢性手部湿疹和白癜风。 ARQ-255 是为治疗斑秃而开发的。
公司简介
公司代码ARQT
公司名称Arcutis Biotherapeutics Inc
上市日期Jan 31, 2020
CEOMr. Todd Franklin Watanabe
员工数量342
证券类型Ordinary Share
年结日Jan 31
公司地址3027 Townsgate Road
城市WESTLAKE VILLAGE
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编91361
电话18054185006
网址https://arcutis.com/
公司代码ARQT
上市日期Jan 31, 2020
CEOMr. Todd Franklin Watanabe
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Bhaskar Chaudhuri, Ph.D.
Dr. Bhaskar Chaudhuri, Ph.D.
Independent Director
Independent Director
917.81K
+0.84%
Mr. Todd Franklin Watanabe
Mr. Todd Franklin Watanabe
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
721.32K
-0.28%
Dr. Howard G. Welgus, M.D.
Dr. Howard G. Welgus, M.D.
Independent Director
Independent Director
100.21K
-8.42%
Mr. Masaru (Mas) Matsuda, Esq., J.D.
Mr. Masaru (Mas) Matsuda, Esq., J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
78.26K
-8.03%
Ms. Latha Vairavan
Ms. Latha Vairavan
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
65.10K
--
Ms. Sue-Jean Lin
Ms. Sue-Jean Lin
Independent Director
Independent Director
26.73K
+39.78%
Mr. Patrick J. Heron
Mr. Patrick J. Heron
Independent Chairman of the Board
Independent Chairman of the Board
26.43K
+40.42%
Ms. Neha Krishnamohan
Ms. Neha Krishnamohan
Independent Director
Independent Director
23.36K
+48.32%
Ms. Terrie J. Curran
Ms. Terrie J. Curran
Independent Director
Independent Director
--
--
Ms. Halley E. Gilbert, J.D.
Ms. Halley E. Gilbert, J.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Bhaskar Chaudhuri, Ph.D.
Dr. Bhaskar Chaudhuri, Ph.D.
Independent Director
Independent Director
917.81K
+0.84%
Mr. Todd Franklin Watanabe
Mr. Todd Franklin Watanabe
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
721.32K
-0.28%
Dr. Howard G. Welgus, M.D.
Dr. Howard G. Welgus, M.D.
Independent Director
Independent Director
100.21K
-8.42%
Mr. Masaru (Mas) Matsuda, Esq., J.D.
Mr. Masaru (Mas) Matsuda, Esq., J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
78.26K
-8.03%
Ms. Latha Vairavan
Ms. Latha Vairavan
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
65.10K
--
Ms. Sue-Jean Lin
Ms. Sue-Jean Lin
Independent Director
Independent Director
26.73K
+39.78%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
Suvretta Capital Management, LLC
9.58%
Jennison Associates LLC
9.32%
Rubric Capital Management LP
9.20%
Frazier Life Sciences Management, L.P.
7.37%
BlackRock Institutional Trust Company, N.A.
6.63%
Other
57.89%
持股股东
持股股东
占比
Suvretta Capital Management, LLC
9.58%
Jennison Associates LLC
9.32%
Rubric Capital Management LP
9.20%
Frazier Life Sciences Management, L.P.
7.37%
BlackRock Institutional Trust Company, N.A.
6.63%
Other
57.89%
股东类型
持股股东
占比
Investment Advisor
32.24%
Investment Advisor/Hedge Fund
31.96%
Hedge Fund
29.96%
Private Equity
7.39%
Research Firm
4.30%
Individual Investor
2.19%
Venture Capital
1.84%
Sovereign Wealth Fund
0.45%
Bank and Trust
0.42%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
477
132.39M
111.07%
-21.95M
2025Q1
487
132.87M
111.51%
-24.00M
2024Q4
453
136.04M
114.96%
-23.73M
2024Q3
433
136.12M
116.66%
-19.10M
2024Q2
416
134.94M
116.78%
-20.37M
2024Q1
392
131.83M
115.81%
+2.26M
2023Q4
366
104.30M
108.66%
+5.22M
2023Q3
364
79.57M
131.78%
-15.32M
2023Q2
359
84.02M
139.44%
-6.66M
2023Q1
352
83.59M
140.11%
+3.40M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Suvretta Capital Management, LLC
11.42M
9.58%
+23.84K
+0.21%
Mar 31, 2025
Jennison Associates LLC
11.36M
9.53%
-978.92K
-7.93%
Mar 31, 2025
Rubric Capital Management LP
10.97M
9.2%
--
--
Mar 31, 2025
Frazier Life Sciences Management, L.P.
8.79M
7.37%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
7.91M
6.63%
-197.41K
-2.44%
Mar 31, 2025
The Vanguard Group, Inc.
6.79M
5.7%
+373.66K
+5.82%
Mar 31, 2025
Polar Capital LLP
6.71M
5.63%
-670.91K
-9.09%
Mar 31, 2025
State Street Global Advisors (US)
4.47M
3.75%
-476.52K
-9.63%
Mar 31, 2025
Gilder Gagnon Howe & Co. LLC
4.10M
3.44%
+193.06K
+4.95%
Mar 31, 2025
Morgan Stanley & Co. LLC
3.08M
2.58%
-403.45K
-11.59%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Simplify Health Care ETF
4.4%
Virtus LifeSci Biotech Clinical Trials ETF
0.93%
SPDR S&P Biotech ETF
0.55%
First Trust Small Cap Growth AlphaDEX Fund
0.49%
Direxion Daily S&P Biotech Bull 3X Shares
0.31%
Federated Hermes MDT Small Cap Core ETF
0.28%
First Trust Small Cap Core Alphadex Fund
0.27%
ProShares Ultra Nasdaq Biotechnology
0.19%
Invesco Nasdaq Biotechnology ETF
0.19%
Inspire Small/Mid Cap ESG ETF
0.17%
查看更多
Simplify Health Care ETF
占比4.4%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.93%
SPDR S&P Biotech ETF
占比0.55%
First Trust Small Cap Growth AlphaDEX Fund
占比0.49%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.31%
Federated Hermes MDT Small Cap Core ETF
占比0.28%
First Trust Small Cap Core Alphadex Fund
占比0.27%
ProShares Ultra Nasdaq Biotechnology
占比0.19%
Invesco Nasdaq Biotechnology ETF
占比0.19%
Inspire Small/Mid Cap ESG ETF
占比0.17%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
